ArticleSexual medicine2018
Intralymphatic Immunotherapy With Autologous Semen in a Korean Man With Post-Orgasmic Illness Syndrome.
Article in Sexual medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 32 citations in OpenAlex.
- Recognition and practice patterns of sexual medicine experts towards postorgasmic illness syndrome.International journal of impotence research · 2025Article
- Post orgasmic illness syndrome: a review.International journal of impotence research · 2025Review
- A clinical guide to rare male sexual disorders.Nature reviews. Urology · 2024Review
- Clinical characteristics, allergic response to autologous semen, and desensitization in patients with postorgasmic illness syndrome.Sexual medicine · 2023Article
- Intensified Hyposensitization Is an Effective Treatment of Postorgasmic Illness Syndrome (POIS).Sexual medicine · 2022Article
- The first Tunisian case of postorgasmic illness syndrome: A case report.Clinical case reports · 2021Article
- Article
- Clinical experience with post-orgasmic illness syndrome (POIS) patients-characteristics and possible treatment modality.International journal of impotence research · 2021Observational
- First assessment of the validity of the only diagnostic criteria for postorgasmic illness syndrome (POIS).International journal of impotence research · 2019Article
- Post orgasmic illness syndrome: what do we know till now?Basic and clinical andrology · 2019Article
- Novel treatment for post-orgasmic illness syndrome: a case report and literature review.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-orgasmic illness syndrome (POIS) is a very rare disease characterized by local allergic symptoms and transient flu-like illness that nearly always occur after masturbation, coitus, or spontaneous ejaculation and last for 2 to 7 days. In a previous case report, 2 patients with POIS received hyposensitization therapy composed of multiple subcutaneous injections of autologous semen that resulted in a gradual decrease of symptoms. However, this procedure requires patients to endure pain and discomfort during frequent subcutaneous injections and preceding masturbations to obtain the autologous semen used for therapy. Recent studies have suggested that intralymphatic immunotherapy is a promising new method of allergen-specific immunotherapy against allergic diseases, showing a faster onset and longer duration of therapeutic effects after only several intralymphatic injections. We report on a case of a Korean man with POIS who received intralymphatic immunotherapy that alleviated POIS-related symptoms and in whom the existence of semen-specific immunoglobulin E was confirmed using immunoglobulin E immunoblotting and enzyme-linked immunosorbent assay. Kim TB, Shim YS, Lee, SM, et al. Intralymphatic Immunotherapy With Autologous Semen in a Korean Man With Post-Orgasmic Illness Syndrome. Sex Med 2018;6:174-179.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.